TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the €œCompany€) announces that, in connection with its creditor protection proceedings under the Companies Creditors...
Acerus Files For CCAA Protection
TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board...
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “Note”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. The securityholder representative and Acerus agreed that the amount of the note would be increased to US$7.75 million. Repayment of the Note would be done via a payment schedule commencing the last business day of each calendar quarter following the calendar quarter in which the achievement of the first commercial sale of NOCTIVA in the United States (“First Commercial Sale”). The increase in the face value of the promissory note reflects the estimated interest cost associated with the progress payment schedule noted below. Payments will now occur as follows:
A month after Acerus Pharmaceuticals announced the resignation of its chief financial officer, the company says it's undergoing a strategic review to stay afloat.
TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective November 20, 2022.
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase its existing secured loan facility (the “Loan Facility”) from US$37.945 million to US$47.945 million. This increase will be made available to the Company by way of two advances of US$5.0 million each on August 5 and 8, 2022 under a secured grid promissory note with First Generation.
TORONTO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 before the market opens. The company will also host a conference call on Tuesday, August 9, 2022 at 10:00 a.m. Eastern Time.
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on...
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with...